Abstract 7236: First successful engraftment of human pancreatic cancer cells in an immunocompromised porcine model to test tumor ablation by high-frequency irreversible electroporation (H-FIRE)

Abstract Pancreatic tumor is difficult to treat due to late diagnosis, critical tumor location, limited surgical options, and high metastatic potential. High-frequency irreversible electroporation (H-FIRE) is a non-thermal ablation technique that uses high-voltage electric pulses to create permanent nanopores in cell membranes, disrupting homeostasis and inducing cell death. This study established the feasibility of using H-FIRE to ablate pancreatic tumors in an immunocompromised porcine model were RAG2/IL2RG double knockout pigs. Panc1 human pancreatic cancer cells were orthotopically injected into the pancreas of these pigs. 3 weeks post-injection, successful tumor engraftment and growth were observed during treatment. We successfully accessed and treated the tumors using H-FIRE, with clear ablation zones and preservation of surrounding tissue confirmed by histopathology. The treatment also showed minimal local muscle contraction. This study demonstrated the first robust large-animal model of H-FIRE-treated human pancreatic cancer with safety and efficacy. Future work will explore the potential of these immunocompromised porcine models for developing advanced therapeutic strategies to enhance tumor ablation by H-FIRE. Citation Format: Manali Powar, Tamalika Paul, Edward Jacobs, Sherrie Clark-Deener, Christopher Byron, Sheryl Coutermarsh-Ott, Katie Orr, Maxx Steinmann, levente Gal, Cassandra Poole, Carley Elliott, Mackenzie Woolls, Madeline Mott, Julio Arroyo, Zaid Salameh, Hannah Ivester, Rafael V. Davalos, Irving Coy Allen. First successful engraftment of human pancreatic cancer cells in an immunocompromised porcine model to test tumor ablation by high-frequency irreversible electroporation (H-FIRE) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7236.